問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Shin Kong Memorial Wu Ho-Su Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 111Taipei CityShih Lin

Recruiting Trial

51Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

139Cases

2014-08-31 - 2016-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-07-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2010-01-08 - 2011-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2014-02-01 - 2016-01-31

Phase III

Acute Stroke Or Transient IsChemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES

  • Condition/Disease

    Patients with an acute cerebral ischemic event (minor stroke/high-risk TIA) and high risk of subsequent ischemic stroke, who could be randomised within 24 hours of symptom onset

  • Test Drug

    Ticagrelor

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

林瑞泰
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2014-02-01 - 2019-01-25

Phase III

A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    BRILINTA

Participate Sites
25Sites

Recruiting1Sites

Terminated24Sites

2018-01-22 - 2019-12-31

Phase III

A Randomized, Double-Blinded, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack

  • Condition/Disease

    Acute Ischemic Stroke or Transient ischaemic attack

  • Test Drug

    BRILINTA

Participate Sites
16Sites

Recruiting15Sites

Study ended1Sites

李宗海
Linkou Chang Gung Medical Foundation

Division of Neurology

林秀芬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2004-02-01 - 2005-02-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2008-09-01 - 2010-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-09-01 - 2013-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2015-11-01 - 2019-12-31

Phase III

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    Bexagliflozin Tablets

Participate Sites
9Sites

Terminated7Sites

江晨恩
Taipei Veterans General Hospital

賴文德
Kaohsiung Municipal Gangshan Hospital

未分科

1 6 7 8 9 10 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB